A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals' dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi-Pasteur-MSD's DTPa-IPV (Tetravac), when co-administered with MMRV (Priorix Tetra) in 5 to 6-year-old healthy children.

Trial Profile

A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals' dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi-Pasteur-MSD's DTPa-IPV (Tetravac), when co-administered with MMRV (Priorix Tetra) in 5 to 6-year-old healthy children.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs DTaP poliovirus vaccine (Primary) ; DTaP vaccine; Measles mumps and rubella virus vaccine
  • Indications Diphtheria; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
  • Focus Pharmacodynamics
  • Acronyms dTpa-IPV010
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 11 Dec 2009 Actual patient number (303) added as reported by ClinicalTrials.gov.
    • 11 Dec 2009 Status changed from active, no longer recruiting to completed.= as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top